Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study
- PMID: 26888800
- DOI: 10.1093/bja/aev556
Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study
Abstract
Background: Platelet inhibition is mandatory therapy after percutaneous coronary intervention (PCI). Withdrawal of oral antiplatelet agents has been linked to increased incidence of postoperative adverse cardiac events in post-PCI patients having non-cardiac surgery (NCS). There is limited knowledge of temporal changes in platelet inhibition in this high-risk surgical population. We therefore performed a multicentre prospective cohort study evaluating perioperative platelet function and its association with postoperative major adverse cardiac events (MACE).
Methods: In 201 post-PCI patients having NCS, we assessed the association between platelet function and postoperative MACE. We performed perioperative platelet function testing using a platelet mapping assay (PMA). Troponin-I was measured every 8 h for 2 days, then daily until day 5. Myocardial infarction was assessed using the third universal definition. We used multivariable logistic regression to assess the association between platelet inhibition and MACE.
Results: Major adverse cardiac events occurred in 40 patients within 30 days of surgery. Thirty-two of these events were non-ST-elevation myocardial infarction, four ST-elevation myocardial infarction, and four exacerbation of congestive heart failure. We were unable to show an association between platelet inhibition and MACE. The PMA showed declining levels of platelet inhibition the longer the antiplatelet therapy was withheld before surgery. Logistic regression did not show an association between preoperative platelet function or the type of stent and MACE. We found an increased cardiac risk of MACE after surgery within 6 weeks of PCI.
Conclusions: The incidence of MACE in patients undergoing NCS after previous PCI is high in spite of adequate perioperative antiplatelet therapy.
Clinical trial registration: NCT 01707459 (registered at http://www.clinicaltrials.gov).
Trial registration: ClinicalTrials.gov NCT01707459.
Keywords: major adverse cardiac events; non-cardiac surgery; percutaneous coronary intervention; platelet inhibition.
© The Author 2016. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Comment in
-
Insights into myocardial infarction after noncardiac surgery in patients with a prior coronary artery stent.Br J Anaesth. 2016 May;116(5):584-6. doi: 10.1093/bja/aew111. Br J Anaesth. 2016. PMID: 27106960 No abstract available.
Similar articles
-
Anti-inflammatory Therapy Progress in Major Adverse Cardiac Events after PCI: Chinese and Western Medicine.Chin J Integr Med. 2023 Jul;29(7):655-664. doi: 10.1007/s11655-023-3638-8. Epub 2023 May 18. Chin J Integr Med. 2023. PMID: 37198377 Review.
-
[Perioperative Management for Prevention of Cardiac Complications in General Thoracic Surgery].Kyobu Geka. 2017 Jul;70(8):639-642. Kyobu Geka. 2017. PMID: 28790281 Review. Japanese.
-
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.Thromb Haemost. 2015 Feb;113(2):272-82. doi: 10.1160/TH14-05-0436. Epub 2014 Oct 2. Thromb Haemost. 2015. PMID: 25274620
-
Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.JACC Cardiovasc Interv. 2014 Oct;7(10):1117-27. doi: 10.1016/j.jcin.2014.04.020. Epub 2014 Sep 17. JACC Cardiovasc Interv. 2014. PMID: 25240538
-
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.J Interv Cardiol. 2013 Jun;26(3):221-7. doi: 10.1111/j.1540-8183.2013.12024.x. Epub 2013 Feb 4. J Interv Cardiol. 2013. PMID: 23373620 Clinical Trial.
Cited by
-
What should be done when appropriate antiplatelet therapy fails to prevent stent thrombosis? Two case reports.Clin Case Rep. 2023 Jun 26;11(6):e7625. doi: 10.1002/ccr3.7625. eCollection 2023 Jun. Clin Case Rep. 2023. PMID: 37384231 Free PMC article.
-
Comparison of Early and Late Surgeries after Coronary Stent Implantation in Patients with Normal Preoperative Troponin Level: A Retrospective Study.J Clin Med. 2023 Mar 27;12(7):2524. doi: 10.3390/jcm12072524. J Clin Med. 2023. PMID: 37048612 Free PMC article.
-
Consensus Decision-Making for the Management of Antiplatelet Therapy before Non-Cardiac Surgery in Patients Who Underwent Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents: A Cohort Study.J Am Heart Assoc. 2021 Apr 20;10(8):e020079. doi: 10.1161/JAHA.120.020079. Epub 2021 Apr 10. J Am Heart Assoc. 2021. PMID: 33843258 Free PMC article.
-
Association between intraoperative hypotension and postoperative myocardial injury in patients with prior coronary stents undergoing high-risk surgery: a retrospective study.J Anesth. 2020 Apr;34(2):257-267. doi: 10.1007/s00540-020-02736-4. Epub 2020 Jan 21. J Anesth. 2020. PMID: 31965251
-
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD012584. doi: 10.1002/14651858.CD012584.pub2. Cochrane Database Syst Rev. 2018. PMID: 30019463 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous